Assessing efficacy in early-phase cancer prevention trials: The case of oral premalignancy

Cancer Prevention Research

Volumn 1, Issue 5, 2008, Pages 312-315

  Szabo, Eva ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADENOMA; CANCER DIAGNOSIS; CARCINOMA; DISEASE COURSE; HUMAN; MOUTH TUMOR; NEOPLASM; NOTE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOMA; BIOLOGICAL MARKERS; CARCINOMA; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; MOUTH NEOPLASMS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 61549088503     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0171     Document Type: Review

References (35)

1. Szabo E. Primer: First do no harm-when is it appropriate to plan a cancer prevention clinical trial? Nat Clin Pract Oncol 2008;5:309-312.
2. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8: 314-46.
3. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Int Med 2007; 146:376-89.
4. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Eng J Med 2007;356:2131-42.
5. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-13.
6. Cho NL, Redston M, Zauber AG, et al. Aberrant crypt foci in the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res 2008;1:21-31.
7. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev 2002;2:1-9.
8. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 1990;82:555-60.
9. Meyskens FL, Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-8.
10. Szabo E. Lung epithelial proliferation: a biomarker for chemoprevention trials? J Natl Cancer Inst 2001;93:1042-3.
11. Szabo E. Proliferative changes in chemoprevention trials: learning from secondary endpoints. J Natl Cancer Inst 2007;99:1565-7.
12. Human papillomaviruses. Lyon (France): IARC; 2007.
13. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
14. Wirth LJ, Krane JF, Li Y, et al. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res 2008;1:339-48.
15. Silverman S, Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984;53:563-8.
16. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Eng J Med 1986;315:1501-5.
17. Papadimitrakopoulou VA, William WN, Dannenberg AJ, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14:2095-101.
18. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6: 1702-10.
19. Poh CF, Zhang L, Anderson DW, et al. Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients. Clin Cancer Res 2006;12:6716-22.
20. Poh CF, Ng SP, Williams PM, et al. Direct fluorescence visualization of clinically occult high-risk oral premalignant disease using a simple hand-held device. Head Neck 2007;29:71-6.
21. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998;90: 1545-51.
22. Zhang L, Poh CF, Lam WL, et al. Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection. Oral Oncol 2001;37: 505-12.
23. Papadimitrakopoulou VA, Lee JJ, William WN, et al. Randomized trial of 13-cis retinoic acid versus retinyl palmitate with or without β-carotene in oral premalignancy. J Clin OncolIn press 2008.
24. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 2007; 13:4035-41.
25. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6: 357-62.
26. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-β in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995;332:1405-10.
27. Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003;21:4546-52.
28. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 2003; 95:198-205.
29. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645-50.
30. Csiki I, Morrow JD, Sandler A, et al. Targeting cyclooxygenase-2 in recurrent non-small cell lungcancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005;11:6634-40.
31. Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007;99:545-57.
32. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355: 873-84.
33. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
34. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
35. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebocontrolled trials: the cross trial safety analysis. Circulation 2008;117:2104-13